PODDMEDIUM SIGNALFINANCIAL10-K

PODD delivered strong revenue growth of 31% and operating income surge of 53%, but net income declined 41% due to increased investments in R&D and operations.

The company is experiencing robust top-line growth in its insulin delivery systems while strategically investing heavily in R&D (up 37%) and expanding operations, which temporarily compressed net margins. The substantial increase in operating cash flow (+32%) and stockholders' equity (+25%) indicates the business fundamentals remain strong despite the earnings decline.

Comparing 2026-02-18 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

PODD demonstrated impressive operational momentum with revenue growing 31% to $2.7B and gross profit expanding 34% to $1.9B, driving operating income up 53% to $474M. However, aggressive investments in R&D (+37%) and SG&A (+27%), combined with what appears to be higher tax expenses or one-time charges, caused net income to fall 41% to $247M despite strong operating performance. The healthy 32% growth in operating cash flow to $569M and 25% increase in stockholders' equity to $1.5B suggests the company is successfully reinvesting profits for future growth while maintaining strong cash generation capabilities.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+53.4%
$308.9M→$473.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+53.4%
$124.9M→$191.6M

Capital expenditure jumped 53.4% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
-40.9%
$418.3M→$247.1M

Net income declined 40.9% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+37.1%
$219.6M→$301.1M

R&D investment increased 37.1% — signals commitment to future product development, though near-term margin impact.

Gross Profit
P&L
+34.2%
$1.4B→$1.9B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Operating Cash Flow
Cash Flow
+32.3%
$430.3M→$569.3M

Operating cash flow surged 32.3% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+30.7%
$2.1B→$2.7B

Strong top-line growth of 30.7% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+28.7%
$528.4M→$680.1M

Current liabilities rose 28.7% — increased short-term obligations, watch current ratio.

SG&A Expense
P&L
+27%
$917.2M→$1.2B

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Stockholders Equity
Balance Sheet
+25.1%
$1.2B→$1.5B

Equity base grew 25.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-18
PRIOR — 2025-02-21
ADDED
Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among children and young adults, due primarily to increasing obesity.
and international insulin-requiring type 2 diabetes population and the U.S.
MDI therapy also requires a separate injection of a long-acting (basal) insulin, to control glucose levels between meals.
The small, lightweight, self-adhesive disposable tubeless Omnipod device ( Pod ), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back.
Omnipod products provide for virtually pain-free automated cannula (a small flexible tube) insertion through which insulin is delivered, eliminating the need for MDI or the use of pump and tubing.
We refer to the delivery of insulin with the Pod as Pod therapy.
The Pod can be controlled by an Insulet-provided handheld device or, in the U.S., a user-downloaded Android app or iOS app, with full smartphone compatibility.
s ( Abbott ) FreeStyle Libre 2 Plus sensor ( Libre 2 Plus ) in various markets.
In 2026, we launched Omnipod Discover, a data analytics and reporting platform designed to give users, their caregivers, and health care providers actionable insights.
Omnipod Discover helps to identify trends and is intended to provide supplemental data to support diabetes management for Omnipod 5 users and to aid healthcare providers in patient care.
REMOVED
Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among the younger population, due primarily to increasing obesity.
and international insulin-intensive type 2 diabetes population and the U.S.
MDI therapy may also require a separate injection of a long-acting (basal) insulin, to control glucose levels between meals; typically, once or twice per day.
The small, lightweight, self-adhesive disposable tubeless Omnipod device ( Pod ), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube (called a cannula).
The embedded algorithm utilizes these glucose values to predict glucose levels into the future and automatically adjusts insulin dosing intended to improve time-in-range and reduce the occurrence of blood glucose highs and lows.
s ( Abbott ) FreeStyle Libre 2 Plus sensor ( Libre 2 Plus ) in various markets as depicted under Markets and Distribution Methods .
Omnipod DASH communicates wirelessly, provides for virtually pain-free automated cannula insertion, and eliminates the need for MDI therapy or the use of pump and tubing.
With certifications from the Diabetes Technology Society s Standard for Wireless Diabetes Device Security cybersecurity and assurance standard and program as well as from the International Organization for Standardization ( ISO ), Insulet is globally recognized for incorporating the highest standards for cybersecurity, information security, and safety, including secure data transfer between the Pod and PDM, as well as secure cloud storage.
In some cases, we seek reimbursement from government administrative payors and/or health insurance companies.
In the United States, consumers generally have commercial insurance, Medicare or Medicaid coverage that pays for the product.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →